Masimo has made a $40 million cash offer for Lidco, which seems to make sense to analysts.

Amanda Pedersen

November 2, 2020

2 Min Read
Image by tumsasedgars - Adobe Stock

There wasn't a lot of fanfare around Masimo's $40 million cash offer for Lidco on Monday, but medtech analysts commenting on the deal announcement seem to think the hemodynamic monitoring tuck-in is a good fit.

Masimo Corporation said in a regulatory filing that it has established Masimo LHC Limited specifically for the purpose of making an offer for UK-based Lidco.  

"While this is a relatively small transaction, we expect [Masimo] to be able to scale [Lidco's] portfolio given [Masiomo's] larger footprint," said Mike Matson, a medtech analyst at Needham & Co.

The analyst went on to say in his report Monday that he expects Masimo to continue to use its $719 million balance sheet to pursue tuck-in acquisitions of complementary products, and he's not alone in that opinion.

"M&A is a priority for [Masimo], and we think this transaction fits well with the company’s in-hospital monitoring portfolio," Marie Thibault, a medtech analyst at BTIG, wrote in her report Monday. "The acquisition is expected to close soon.

As Thibault pointed out, the hemodynamic monitoring space has seen a few acquisitions in the past couple of years. She mentioned Edwards Lifesciences' $100 million acquisition of CAS Medical Systems and Baxter's $190 million acquisition of Cheetah Medical as examples. Both of those deals were announced in 2019.

Masimo's hunt for 'fixer-uppers in great neighborhoods'

In an earnings call last year, Masimo CEO Joe Kiani talked about the need to create diversification for the company.

"We want to create diversification for Masimo. ... I don't want the Kodak movement," Kiani said during the company's second quarter earnings call.

Kiani said Masimo was more interested in M&A opportunities that are "totally separate" from its business rather than adjacent to it, he said at the time. "We're looking for opportunities in big markets" that are estimated to be about $3 billion or $4 billion in size and growing and seeing at or near double-digit growth.

"We're not looking for [a] $1 billion, $2 billion type of acquisition," Kiani said. "We're looking for what I call fixer-uppers in great neighborhoods."

About the Author(s)

Amanda Pedersen

Amanda Pedersen is a veteran journalist and award-winning columnist with a passion for helping medical device professionals connect the dots between the medtech news of the day and the bigger picture. She has been covering the medtech industry since 2006.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like